HTML Microdata document

This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/chemspider/
foaf	http://xmlns.com/foaf/0.1/
n20	http://linked.opendata.cz/resource/drugbank/company/
n13	http://linked.opendata.cz/resource/mesh/concept/
n14	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/chebi/
n29	http://linked.opendata.cz/resource/drugbank/dosage/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/wikipedia/
n28	http://bio2rdf.org/drugbank:
n21	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/pharmgkb/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/kegg-compound/
adms	http://www.w3.org/ns/adms#
n22	http://linked.opendata.cz/resource/drugbank/patent/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/pubchem-compound/
n26	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n24	http://linked.opendata.cz/resource/drugbank/medicinal-product/
n16	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/pubchem-substance/
n12	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n18	http://www.drugs.com/cdi/
n10	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/drugbank/
n27	http://www.rxlist.com/cgi/generic2/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n9	http://linked.opendata.cz/resource/drugbank/drug/DB01091/identifier/national-drug-code-directory/
n6	http://linked.opendata.cz/resource/atc/
n5	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB01091
rdf:type: n3:Drug
n3:description: Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine works by inhibiting the synthesis of sterols by inhibiting squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes.
n3:dosage: n29:271B64B2-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # McNeely W, Spencer CM: Butenafine. Drugs. 1998 Mar;55(3):405-12; discussion 413. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9530545 # Singal A: Butenafine and superficial mycoses: current status. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):999-1005. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18624686 # Gupta AK: Butenafine: an update of its use in superficial mycoses. Skin Therapy Lett. 2002 Sep;7(7):1-2, 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12432425 # Mingeot-Leclercq MP, Gallet X, Flore C, Van Bambeke F, Peuvot J, Brasseur R: Experimental and conformational analyses of interactions between butenafine and lipids. Antimicrob Agents Chemother. 2001 Dec;45(12):3347-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11709307 # Syed TA, Maibach HI: Butenafine hydrochloride: for the treatment of interdigital tinea pedis. Expert Opin Pharmacother. 2000 Mar;1(3):467-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11249531 # Reyes BA, Beutner KR, Cullen SI, Rosen T, Shupack JL, Weinstein MB: Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Int J Dermatol. 1998 Jun;37(6):450-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9646136 # Iwatani W, Arika T, Yamaguchi H: Two mechanisms of butenafine action in Candida albicans. Antimicrob Agents Chemother. 1993 Apr;37(4):785-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8494375
n3:group: approved
n3:halfLife: Following topical application, a biphasic decline of plasma butenafine concentrations was observed with the half-lives estimated to be 35 hours initial and over 150 hours terminal.
n3:indication: For the topical treatment of the following dermatologic infections: tinea (pityriasis) versicolor due to M. furfur, interdigital tinea pedis (athlete’s foot), tinea corporis (ringworm) and tinea cruris (jock itch) due to E. floccosum, T. mentagrophytes, T. rubrum, and T. tonsurans.
owl:sameAs: n26:DB01091 n28:DB01091
dcterms:title: Butenafine
adms:identifier: n8:C08067 n9:0378-6151-46 n10:DB01091 n14:3238 n15:2390 n16:46506191 n19:2484 n21:PA164745478 n23:Butenafine
n3:mechanismOfAction: Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells.
n3:packager: n20:271B64AC-363D-11E5-9242-09173F13E4C5 n20:271B64AD-363D-11E5-9242-09173F13E4C5 n20:271B64AB-363D-11E5-9242-09173F13E4C5
n3:patent: n22:5021458
n3:synonym: Butenafine 4-Tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine (4-Tert-butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine (4-Tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine Butenafinum N-(P-Tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine Butenafina
n3:salt
n3:synthesisReference: "DrugSyn.org":http://www.drugsyn.org/Butenafine.htm
n12:hasConcept: n13:M0185247
foaf:page: n18:butenafine-cream.html n27:butenafine.htm
n3:IUPAC-Name: n4:271B64B7-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B64BD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B64BC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B64B9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B64BA-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B64BB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B64B5-363D-11E5-9242-09173F13E4C5 n4:271B64CC-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B64B3-363D-11E5-9242-09173F13E4C5 n4:271B64B6-363D-11E5-9242-09173F13E4C5 n4:271B64CD-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B64B4-363D-11E5-9242-09173F13E4C5
n5:hasATCCode: n6:D01AE23
n3:H-Bond-Acceptor-Count: n4:271B64C3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B64C4-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B64BE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B64BF-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B64C1-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B64C0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B64C2-363D-11E5-9242-09173F13E4C5
n3:absorption: The total amount absorbed through the skin into the systemic circulation has not been quantified.
n3:affectedOrganism: Fungi
n3:casRegistryNumber: 101828-21-1
n3:category
n3:containedIn: n24:271B64B0-363D-11E5-9242-09173F13E4C5 n24:271B64B1-363D-11E5-9242-09173F13E4C5 n24:271B64AE-363D-11E5-9242-09173F13E4C5 n24:271B64AF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n4:271B64C8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B64CA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B64CB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B64C7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B64C6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B64C9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B64B8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B64C5-363D-11E5-9242-09173F13E4C5